Nimble Ventures is a family office that makes venture capital investments. The firm was founded in 2014 and is based in San Francisco, CA.

Nimble Ventures

Head and Heart Capital invest in angel and seed stage impact focused ventures.

Head and Heart Capital

Thiel Capital focuses on investments in various industries such as artificial intelligence, drones, and healthcare. Located in Los Angeles, Thiel Capital provides strategic and operational support for Peter’s many investment initiatives and entrepreneurial endeavors. Related organizations include Founders Fund, Mithril, Valar Ventures, and The Thiel Foundation.

Thiel Capital

What If Ventures invests in stigmatized verticals within the healthcare market. For too long, stigma has artificially suppressed demand for care in indications such as mental health, fertility, and many others.  Societal changes are creating markets where stigma once stood in the way of people getting the care they need. The firm was founded in 2019 by Stephen Hays, after his own personal struggles with mental health and addiction fueled his desire to see more funding for solutions in that space.  Since then, the firm has broadened its aperture and has deployed nearly $80mm into more than 60 disruptive healthcare startups.

What If Ventures

Masnavi is a globally-focused VC firm investing in early-stage, impact-oriented and talent-driven startups that provide disruptive technologies and solutions within such sectors as Biotechnology, Mental Health, Sustainable Agtech and Foodtech, Spatial Intelligence , Space Exploration and Telecommunication.

Masnavi Capital

GrayBella Capital is a venture capital firm that invests in technology and healthcare-related companies.

GrayBella Capital

Subversive Capital is dedicated to investing in radical companies whose core missions subvert the status quo and require sophisticated government and regulatory strategies for success.

Subversive Capital

Apeiron Investment Group is the family office and private investment firm of entrepreneur and investor Christian Angermayer. With more than USD 2.5 billion under management and over 50 people across five international locations, Apeiron focuses on Life Sciences, FinTech & Crypto, FutureTech, and Experiences, Hospitality & Happiness. Apeiron has a global approach and deploys its capital across the entire company lifecycle, from founding companies in-house, seed/start-up investments, to large-scale investments in listed companies.

Apeiron Investment Group

Bracket Capital is an alpha-driven global investment manager focused on high-growth, later-stage, technology-enabled companies. The company was founded in 2017 and is based in West Hollywood, California.

Bracket Capital

They aim to support and nourish passionate entrepreneurs and inspiring brands that will make the daily lives of people healthier, happier, and more enlightened. They’re guided by their own experiences as entrepreneurs, and  they view all of their investments as partnerships—working with the founders to reach their unique goals. As individual investors, they are open to different paths to growth and exit strategies, and this flexibility is central to the promise they make their brands: they’re here to help you win big.

Able Partners

Bail Capital

Single family office of Peter and Robin Lauber investing in residential Real Estate and Venture Capital opportunities

Infinitas Capital

Recharge Capital invests capital and operating resources in technology and business solutions that energize the development of high-potential sectors.

Recharge Capital

Woodline Partners is a private equity firm that focuses on the healthcare and technology sectors. The firm was founded in 2018 and is based in San Francisco, California, United States.

Woodline Partners

Pura Vida Investments is a fundamentally driven, market neutral healthcare-focused investment vehicle. The objective of the firm is to identify and capitalize on structural changes in the healthcare landscape and on inflections in company specific valuations. The firm strives to look past day-to-day volatility and to hone in on major value shifts over the medium to longer term.  The firm’s portfolio is managed by Efrem Kamen and Doron Junger MD and is run in a market neutral fashion, investing across most areas of healthcare, including medical devices, biotechnology, pharmaceuticals, tools, life sciences and healthcare services. The Fund has an optional 10% allocation to designated investments, allowing participation in private and certain illiquid public securities, which is managed by Frank Litvack MD.

Pura Vida Investments

Gaingels is a venture investment syndicate in service of the LGBT+ community and its allies, investing in companies with LGBT+ founders and C-suite leaders at all stages of growth, as well as in more established companies resolved on building more inclusive teams, with a global portfolio of 130+ companies and $70M in deployed investment capital to date.  The Gaingels network also actively supports its portfolio in identifying and recruiting diverse talent to their C-suite and board leadership teams and fosters a vibrant global community of industry leaders, investors, operators, and entrepreneurs who share a common goal for positive social change through business and successful investments.

Gaingels

Alpha Wave is an investment company that has three main verticals; private equity, private credit, and public markets. The objective of the private equity partnerships is to invest in best-in-class venture and growth stage companies and endeavors to be helpful, long-term partners to these exceptional founders and management teams; credit, which includes direct private lending to businesses looking for funding solutions; and public markets in an uncorrelated strategy. Alpha Wave has offices in New York, Miami, London, Monaco, Madrid, Abu Dhabi, Tel Aviv, Bangalore, and Sydney.

Alpha Wave Global

Fearless Ventures is a venture capital firm committed to helping the world's best entrepreneurs become conscious leaders and build businesses for the benefit of all stakeholders. Fearless Ventures was founded by Seth Miller (10-year impact VC) and Dave Kashen (CEO coach to over 100  entrepreneurs and founder of 2 successful startups). Our personal mission is to spread light and love.

Fearless Ventures

Presight Capital is a venture capital firm investing in the most ambitious founders across sectors, stages, and geographies.  Presight takes a global approach to early-stage investment opportunities in software, frontier technologies & biotech, backed by Apeiron, the family office of Christian Angermayer, and a group of world-class investors: Moore Capital, Point72, Mike Novogratz (former CIO of Fortress Investment Group), Martin Chavez (former CFO of Goldman Sachs), Alan Howard (Brevan Howard), Brent Hoberman (Founders Forum), and many successful entrepreneurs and investors who contribute their respective network and experience.

Presight Capital

Highline Capital Management, L.P., is a New York City-based investment firm that focuses on mid and large capitalization U.S. equities long and short. Since its establishment in 1995, Highline has performed fundamental research to create portfolios with attractive risk/return profiles. Highline prides itself on producing a successful risk-adjusted track record relative to comparative U.S. equity market indices.

Highline Capital Management

Catalio Capital Management is a venture capital firm that invests in breakthrough biomedical technology companies. It was created by George Petrocheilos and Dr. Jacob Vogelstein in 2020.

Catalio Capital Management

The firm has a strong focus on the biotech sector in the United States, Europe and Israel, but also selectively invests in fintech and blockchain opportunities.

Korify Capital

The Brkfst Club focuses on gathering like-minded individuals to invest in ground breaking ideas.

The Brkfst Club

FJ Labs is a stage-agnostic investment firm that focuses on marketplaces and consumer-facing startups. Their investments are seed and series A. The investment range of the company is $50,000 to $5,000,000. It invests in Alibaba Group, Beepi, BrightRoll, Betterment, Adore Me, and Earnest.

FJ Labs

Galaxy Investment Partners is a NYC based multi-strategy investment firm that focuses on digital assets and blockchain technology.

Galaxy Investment Partners

Future Ventures is a financial services platform with a focus on disruptive technology companies such as commercial space exploration, deep learning, quantum computing, robotics, AI, blockchain, sustainable transportation, synthetic biology and clean meat. As venture capitalists, the founders of Future Ventures have led founding investments in several companies that had successful IPOs and others that were acquired for over $16 billion in aggregate. Some of our early VC investments include Memphis Meats, Mythic, Nervana, Planet, Rethink Robotics, Skype, SpaceX, Tesla and Zoox. Current board seats include SpaceX, Tesla, and D-Wave.

Future Ventures

A.M. Management & Consulting (AMMC) is a private equity, active investment, and consulting firm. The company was founded to be a specialized advisor to entrepreneurs looking to scale their businesses and drive revenues. AMMC seeks to become a preferred partner for its’ portfolio entities, and to cultivate relationships that last beyond an initial investment. The firm's value-add approach ensures that these companies have access to the necessary tools and operational support needed to facilitate growth.

A.M. Management & Consulting (AMMC)

We are a specialized investment fund in biotechnology that also functions as a company builder. Our mission is to create and support innovative companies, guiding them from inception to commercial launch.  As a dynamic company builder, we provide support to emerging companies in agrowth-focused and innovative environment. We deliver comprehensive services in finance, accounting, legal, compliance, and recruitment to help startups thrive and succeed.

Saya Bio

Valhalla Ventures backs visionary founders building enduring moats.

Valhalla Ventures

ATAI Life Sciences

Promising research and receding stigma are giving investors cannabis-boom flashbacks.

Psychedelic Medicine

<div>
 
 Compass Pathways is a psychedelic biotechnology company founded in 2016 that researches the psychedelic compound psilocybin for treatment-resistant depression.
 
 
 The company&rsquo;s proprietary formulation of synthetic psilocybin, COMP360, received Breakthrough Therapy status from the US Food and Drug Administration (FDA) in 2018. It has completed
 <a href="https://sp-edge.com/updates/14283">
 
 Phase 2
 </a>
 
 trials and plans to conduct Phase 3 trials in December 2022. It also claims to have conducted the world's largest psilocybin therapy trial with 216 patients.&nbsp;
 
 
 It has been granted 10 patents as of September 2022, with several others pending. The company has offices in London and New York. In September 2020, Compass Pathways became the first psychedelic company to be listed on the NASDAQ exchange and raised USD 144 million via a public offering afterward, in April 2021. For
 <a href="https://sp-edge.com/updates/16800">
 
 FY2022
 </a>
 
 net losses widened by 27.6% YoY to USD 91.5 million.&nbsp;
 
 
 Key customers and partnerships&nbsp;
 
 
 The company has partnerships with various institutions, including The Aquilino Cancer Center, Depression, and Bipolar Support Alliance, The Grady Trauma Project, and the National Council of Behavioural Health.&nbsp;
 
 
 Further, the company entered several partnerships in support of its product development initiatives, including 1) Mindful Health Solutions, to research on scalable psilocybin treatment model ( 
 <a href="https://sp-edge.com/updates/29087">
 May 2024
 </a>
 ), 2) Journey Clinical, to develop a deployment and training model for COMP360 ( 
 <a href="https://sp-edge.com/updates/28939">
 April 2024 
 </a>
 ), 3) Hackensack Meridian Health, to support research efforts using psilocybin in mental health treatments ( 
 <a href="https://sp-edge.com/updates/25618">
 January 2024 
 </a>
 ), and 4) Greenbrook TMS, to explore delivery models for COMP360 ( 
 <a href="https://sp-edge.com/updates/25237">
 January 2024 
 </a>
 ).
 
</div>

<div>
 
 UK-based Beckley Psytech is developing a pipeline of psychedelic compounds to eventually create licensed pharmaceutical medicines for neurological and psychiatric disorders including short-lasting unilateral neuralgiform headache attacks (SUNHA), treatment-resistant depression (TRD) and other rare and more common conditions. Its current research is focused on well-characterized psychedelic agents such as psilocybin, but it plans on developing other under researched psychedelic agents as well as new improved versions of existing psychedelics.&nbsp;&nbsp;
 
 
 The company is currently conducting a Phase 1b trial with low-dose psilocybin to treat SUNHA, and plans to initiate Phase 1 trial with a novel formulation of intranasal 5-MeO-DMT for treatment-resistant depression (TRD).&nbsp;
 
 
 Funding and financials
 
 
 Beckley Psytech was formed in 2019, out of Beckley Foundation, a well-established think tank in psychedelic research. In 
 <a href="https://sp-edge.com/updates/25190">
 January 2024
 </a>
 , the company raised USD 50 million in strategic investment from Atai Life Sciences. The new funds were allocated towards speeding up the development of Beckley Psytech&rsquo;s clinical-stage, patent-protected psychedelic candidates, BPL-003 and ELE-101.
 
</div>

Beckley Psytech operates as a psychedelic medicine company. The company is involved in exploring the therapeutic potential of psychedelic substances, such as psilocybin and other compounds, for mental health treatment. The company envisions the integration of clinically validated psychedelic medicines into contemporary medical practices to assist individuals coping with depression and other significantly debilitating neuropsychiatric conditions characterized by a substantial unmet need.

IntelGenx is an oral drug delivery company primarily focused on the development and manufacturing of innovative pharmaceutical oral films based on its proprietary VersaFilm™ technology platform. It provides comprehensive pharmaceutical services to pharmaceutical partners, including R&D, analytical method development, clinical monitoring, IP, and regulatory services. IntelGenx’s state-of-the-art manufacturing facility, established for the VersaFilm™ technology platform, supports lab-scale to pilot and commercial-scale production, offering full-service capabilities to its clients.

Compass Pathways is a mental health care company that focuses on developing therapies for treatment-resistant depression. The company is involved in researching and developing psilocybin therapy, a psychedelic compound found in certain mushrooms, as a potential treatment for depression. Compass Pathways conducts clinical trials and research to assess the safety and efficacy of psilocybin-assisted therapy in patients who have not responded to conventional depression treatments. The company's goal is to bring evidence-based innovation to mental health care and address the significant unmet need for effective and accessible treatments for depression.

At INNOPLEXUS we are helping organisations move to continuous decision-making by generating broader, deeper and faster insights from structured and unstructured private and public data leveraging cutting-edge, patented Artificial Intelligence, Blockchain and advanced analytics technologies. We aim to transform batch decision making in enterprises into a empowered, inspired and faster continuum.    We focus on industries that need to constantly evaluate and improve their efficiency, reduce cost and mitigate risk to keep up with the changing business environment - like global banking, life sciences, and pharmaceutical companies.    In addition to strengthening research efforts, we work to help healthcare organizations leverage technologies to expedite drug development process across all stages - preclinical, clinical, regulatory and commercial. Whether a drug developer is seeking existing research, a medical researcher is searching for alternative treatments, or a practitioner is attempting to find data on a particular disease - increasing access to relevant information removes roadblocks to discovery and fuels rapid growth.   Our Data as a Service (DaaS) and Continuous Analytics as a Service (CaaS) solutions are helping Fortune 500 companies drive business outcomes. We automate the collection, curation, aggregation and analysis, of billions of data points from thousands of data sources, using machine learning, network analysis, ontologies, computer vision and entity normalization.   Founded in 2015, INNOPLEXUS AG is headquartered in Eschborn Germany with offices in Pune, India, and Hoboken, USA.

ATAI is a global biotech company builder that leverages a decentralized, technology- and data-driven platform model to serve millions of people suffering from mental health disorders. The company is committed to acquiring and efficiently developing innovative treatments that address significant unmet medical needs and lead to paradigm shifts in the mental health space. ATAI Life Sciences was founded in 2018 and is based in Munich, Bayern, Germany.

Atai Life Sciences is a clinical-stage biopharmaceutical company focused on developing treatments for mental health disorders. The company's pipeline includes several psychedelic and non-psychedelic compounds targeting conditions such as depression, anxiety, addiction, and schizophrenia. Its candidates include VLS-01, a proprietary oral transmucosal film formulation of DMT for treatment-resistant depression; EMP-01, a R enantiomer of 3,4-Methyl​enedioxy​methamphetamine (R-MDMA) formulation to treat social anxiety disorder; and IBX-210, a ibogaine program to treat opioid use disorder. As per its&nbsp;<a href="https://sp-edge.com/updates/36034">Q3 2024&nbsp;</a>update, the company received FDA approval to advance Phase II trials for VLS-01 buccal film DMT, and EMP-01.

Azenta launches long-read whole genome sequencing test for clinical applications.. Azenta Life Sciences.. product 

Beckley Psytech

Companies conducting research on psychedelic compounds and developing novel therapeutics.

IntelGenX

COMPASS Pathways

McQuade Center for Strategic Research and Development

Camden Partners

Perceptive Advisors

Founders Fund

Skyviews Life Science

Soleus Capital

Noetic Fund

Companies building a patent portfolio of novel analogs and derivatives of first-generation psychedelics and new drug delivery mechanisms. 

Innoplexus

FinLab

Block.one

EOS VC Fund

Atai Life Sciences is a clinical-stage biopharmaceutical company focused on developing treatments for mental health disorders. The company's pipeline includes several psychedelic and non-psychedelic compounds targeting conditions such as depression, anxiety, addiction, and schizophrenia. Its candidates include VLS-01, a proprietary oral transmucosal film formulation of DMT for treatment-resistant depression; EMP-01, a R enantiomer of 3,4-Methyl​enedioxy​methamphetamine (R-MDMA) formulation to treat social anxiety disorder; and IBX-210, a ibogaine program to treat opioid use disorder. As per its&nbsp;<a href="https://sp-edge.com/updates/36034">Q3 2024&nbsp;</a>update, the company received FDA approval to advance Phase II trials for VLS-01 buccal film DMT, and EMP-01.The company acquires and invests in new mental health treatments based on psychedelics and other drugs to treat mental health disorders, including depression, anxiety, and addiction.It has a large stake in Compass Pathways and companies such as DemeRx and Perception Neuroscience. In addition to drug development, ATAI has also made investments in two companies that deliver AI-powered discovery platforms to support drug discovery, including psychedelic compounds. The company formed a subsidiary, Revixia Life Sciences, to develop therapies based on Salvinorin A, a psychedelic compound, for mental health issues.&nbsp;ATAI Life Sciences attracted investments from Peter Thiel and was the highly funded private company, before it went public on Nasdaq markets in June 2021. The company is listed under the ticker symbol “ATAI”.&nbsp;For&nbsp;<a href="https://ir.atai.life/news-releases/news-release-details/atai-life-sciences-reports-fourth-quarter-and-full-year-2023">FY2023</a>, the company’s net losses narrowed by 34.8% YoY to USD 40.2 million, and license revenue significantly increased by 98.9% to USD 0.3 million. Cash and cash equivalents for 2023 were at USD 45 million compared to USD 190.6 million in 2022.

<div>
 
 Canadian biotech firm Core One Labs maintains three primary business operations: 1) developing novel delivery systems for psychedelic medicines, 2) psilocybin manufacturing, and 3) medical clinics to provide psychedelic-assisted psychotherapy. The company has developed proprietary technology with infused strips that dissolve immediately when placed in the patient&rsquo;s mouth to deliver molecules with a higher level of bioavailability. The company plans to advance this technology to incorporate psychedelic molecules, particularly psilocybin.&nbsp;
 
 
 Core One Labs also claims it has discovered a patentable method of producing high-quality psilocybin, which it may license to pharmaceutical companies. Additionally, the company has two psychedelic clinics in Vancouver that currently support clinical trials and maintain a database of more than 275,000 patients. The company acquired Vocan Biotechnologies and Akome Biotech in May 2021 for undisclosed amounts. Akome is developing a patent-pending psychedelic drug formulation for the treatment of Alzheimer&rsquo;s Disease.&nbsp;
 
 
 Core One Labs is listed on the Canadian Securities Exchange (CSE) and OTC markets.
 
 
</div>

Core One Labs

<div>
 
 Vancouver-based Lobe Sciences (formerly GreenStar Biosciences) is a biotechnology company developing psychedelic medicines (microdose applications) and medical devices for efficient drug delivery. The company&rsquo;s main focus is the treatment of mild traumatic brain injury and post-traumatic stress disorder (PTSD). It is also conducting early studies on psilocybin combined with N-acetylcysteine (NAC), and MDMA combined with NAC as a treatment. Lobe is also developing a patent pending nasal mist transducer device for the delivery of medicines directly to the brain&rsquo;s olfactory bulb.&nbsp;
 
 
 In June 2020, Lobe acquired Eleusian Biosciences, a company focused on the development of psychedelic medicine which expanded its intellectual property portfolio with three US patent applications for psychedelic therapeutics. Lobe is also collaborating with the University of Miami&rsquo;s Miller School of Medicine to conduct preclinical studies. After its restructuring and name change, the company started trading on the Canadian Securities Exchange (CSE) in November 2020.
 
 
 
</div>

Lobe Sciences

<div>
 
 Cybin is a psychedelic biotechnology company developing treatments for psychiatric and neurological conditions. Through its Serenity Life Science division, Cybin conducted Phase II of clinical trials on using psilocybin to treat major depressive disorder. Additionally, the company's Nature's Journey division focuses on creating non-psychedelic medicinal and nutraceutical mental health products.
 
 
 Cybin is actively building a patent portfolio, including chemically-synthesized compounds, delivery mechanisms, protocols, and new drug formulations. It has also filed an International Patent Application through the Patent Cooperation Treaty, potentially covering 153 countries.&nbsp;
 
 
 In July 2023, the company announced 
 <a href="https://sp-edge.com/updates/20076">
 EMBARKCT, 
 </a>
 a streamlined version of its EMBARK training program for pivotal studies of lead candidates, CYB003 for major depressive disorder and CYB004 for generalized anxiety disorder, respectively. In 
 <a href="https://sp-edge.com/updates/27577">
 March 2024
 </a>
 , the company received a breakthrough designation from the FDA for CYB003, and expects to initiate Phase III clinical trials for the program by mid-2024.
 
 
 Cybin implements an M&amp;A strategy to grow in the psychedelic industry. It did a reverse takeover of Charmin in June 2020, raising CAD 45 million (USD 35.5 million) for clinical studies. It acquired Adelia Therapeutics in December 2020, adding novel treatments and patent applications. Also in 
 <a href="https://sp-edge.com/updates/21335">
 August 2023 
 </a>
 it acquired 
 <a href="https://sp-edge.com/companies/470858">
 Small Pharma 
 </a>
 in an all-share transaction to strengthen its psychedelic portfolio.&nbsp;
 
 
 Founded in 2019, Cybin is listed on the NEO exchange under the ticker symbol &ldquo;CYBN&rdquo; and was uplisted to the NYSE American Stock Exchange in July 2021 under the same symbol. For FY2023, the company reported a decrease in net loss by 29.7% YoY to CAD 47.5 million (USD 35 million).&nbsp;
 Further in 
 <a href="https://sp-edge.com/updates/33849">
 September 2024
 </a>
 , it completed a 38-to-1 share consolidation of its common stock which reduced the number of outstanding common shares to ~20 million. 
 
 
 Key customers and partnerships&nbsp;
 
 
 In July 2020, Cybin expanded its operations and research activities in the European region via research partnerships and transferred its intellectual property assets to its fully-owned Irish subsidiary (formed in May 2021). In July 2023, the company partnered with 
 <a href="https://sp-edge.com/updates/20455">
 Worldwide Clinical Trials
 </a>
 to develop new psychedelic-based treatment options for mental health conditions, including major depressive disorder. Further, in September 2023, the company partnered with 
 <a href="https://sp-edge.com/updates/22180">
 Fluence
 </a>
 to support Cybin's EMBARK facilitator training program.
 
</div>

Cybin

<div>
 
 Canadian cannabinoid-based therapeutics company BioNxt Solutions
 (formerly Xphyto Therapeutics) announced in November 2020 that it has expanded its drug development program to incorporate a number of psychedelic compounds. This includes substances such as psilocybin, mescaline, LSD, MDMA, and DMT. Xphyto&rsquo;s initial focus is on developing standardized drug formulations with efficient delivery mechanisms for therapeutic use.
 
</div>

BioNxt Solutions

<div>
 
 New York-based Gilgamesh Pharmaceuticals is a biotechnology company developing psychedelic-inspired medicines for neuropsychiatric conditions such as depression, anxiety, addiction, and cognitive deficits. The company has three research programs in its pipeline: 1) Serotonergic Micro-Dose&ndash;a non psychedelic therapeutic treatment for attention deficit hyperactivity disorder (ADHD) and mood/anxiety disorders, 2) Arylcyclohexylamine&ndash;an improved molecule of ketamine for treatment-resistant depression and opiate use disorder, and 3) Novel Ibogaine Analogue&ndash;for the treatment of substance use disorders.&nbsp;
 
 
 Gilgamesh is one of the few psychedelic companies launched by the startup accelerator Y Combinator, and as such enjoys the accelerator&rsquo;s world-famous business expertise and network.
 
 
 Key customers and partnerships
 
 
 In 
 <a href="https://sp-edge.com/updates/29382">
 May 2024
 </a>
 , the company partnered with AbbVie to leverage AbbVie's psychiatric expertise and Gilgamesh's research platform to create novel &quot;neuroplastogens.&quot; 
 
 
 Funding and Financials
 
 
 In 
 <a href="https://sp-edge.com/updates/27575">
 March 2024
 </a>
 , the company received a grant of&nbsp; USD 14 million from the National Institute on Drug Abuse to develop the GM-3009 compound. Prior to this, it raised USD 39 million in a 
 <a href="https://sp-edge.com/updates/15359">
 Series B 
 </a>
 funding round led by Prime Movers Lab in December 2022. 
 
</div>

Gilgamesh Pharmaceuticals

Companies operating digital platforms to deliver psychedelic therapies including psychedelic integration, virtual experiences, and mental coaching and tracking. AI drug discovery companies specializing in psychedelic therapeutics are also included.

Companies operating clinics and treatment centers to deliver psychedelic therapies.

Companies supplying psychedelic compounds through cultivation, chemical synthesis and biosynthesis for medical research and drug development.

<div>
 Atai Life Sciences N.V., a clinical-stage biopharmaceutical company, experienced a net loss of USD 26.3 million in Q3 2024. The company, which develops psychedelic treatments for mental health disorders, emphasizes progress in research throughout the quarter, including FDA approval for Phase II trials of VLS-01 buccal film DMT and EMP-01. VLS-01 is designed to treat treatment-resistant depression, while EMP-01 targets social anxiety disorder.
 Despite a significant net loss, Atai remains hopeful due to its diverse pipeline and anticipates positive outcomes from forthcoming clinical trials.

</div>

ATAI Life Sciences

EDGE Insights

About EDGE

Contact Us

Resources

Area of Focus

Technology Research Made Effortless